By Adria Calatayud

 

GlaxoSmithKline PLC said Tuesday that ViiV Healthcare, the specialist HIV company in which it holds a majority stake, has signed a licensing agreement that gives it exclusive access to Halozyme Therapeutics Inc.'s Enhanze drug-delivery technology.

The collaboration will allow ViiV to develop long-acting medicines for HIV, GlaxoSmithKline said. Under the agreement, ViiV will make an upfront payment of $40 million to Halozyme for am exclusive license to four HIV small and large molecule targets and is obligated to make potential future payments of up to $175 million, subject to hitting some development and commercial milestones, GlaxoSmithKline said.

The U.K. pharmaceutical giant said ViiV plans to start the first experiments with the technology by the end of 2021.

ViiV is majority-owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi & Co. as shareholders.

 

Write to Adria Calatayud at adria.calatayud@dowjones.com

 

(END) Dow Jones Newswires

June 22, 2021 02:31 ET (06:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Jul 2021 to Aug 2021 Click Here for more Halozyme Therapeutics Charts.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Aug 2020 to Aug 2021 Click Here for more Halozyme Therapeutics Charts.